![7-Nitroso-3-(Trifluoromethyl)-5,6,7,8-Tetrahydro-[1,2,4]Triazolo[4,3-a]Pyrazine](https://veeprho.com/wp-content/uploads/2022/07/7-nitroso-3-trifluoromethyl-5-6-7-8-tetrahydro-5B1-2-45Dtriazolo5B4-3-a5Dpyrazine.png)
7-Nitroso-3-(Trifluoromethyl)-5,6,7,8-Tetrahydro-[1,2,4]Triazolo[4,3-a]Pyrazine
It is an impurity present in sitagliptin. It is a dipeptidyl-peptidase inhibitor (DPP-4 inhibitor), which is used for the therapy of type 2 diabetes, sitagliptin is effective in lowering HbA1c, which stimulates insulin secretion when hyperglycemia is present and inhibits glucagon secretion.
Additional information on 7-nitroso-3-(trifluoromethyl)-5 | 6 | 7 | 8-tetrahydro-[1 | 2 | 4]triazolo[4 | 3-a]pyrazine
Catalogue No.
VE009183
CAS No.
N/A
Molecular Formula
C6H6F3N5O
Molecular Weight
221.14 g/mol
Parent drug
Sitagliptin
IUPAC Name
7-nitroso-3-(trifluoromethyl)-5, 6, 7, 8-tetrahydro-[1, 2, 4]triazolo[4, 3-a]pyrazine
Synonyms
N/A
References
Gallwitz, B. (2007). Review of sitagliptin phosphate: a novel treatment for type 2 diabetes. Vascular Health and Risk Management, 3(2), 203–210. https://doi.org/10.2147/vhrm.2007.3.2.203
Status
In-stock
